- Home
- OCX vs DRCT Comparison
OCX vs DRCT Comparison
Compare OCX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- DRCT
- Stock Information
- Founded
- OCX 2009
- DRCT 2018
- Country
- OCX United States
- DRCT United States
- Employees
- OCX N/A
- DRCT N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DRCT Computer Software: Programming Data Processing
- Sector
- OCX Health Care
- DRCT Technology
- Exchange
- OCX Nasdaq
- DRCT Nasdaq
- Market Cap
- OCX 38.7M
- DRCT 38.7M
- IPO Year
- OCX N/A
- DRCT 2022
- Fundamental
- Price
- OCX $2.20
- DRCT $0.61
- Analyst Decision
- OCX Buy
- DRCT Strong Buy
- Analyst Count
- OCX 3
- DRCT 3
- Target Price
- OCX $4.42
- DRCT $21.00
- AVG Volume (30 Days)
- OCX 112.4K
- DRCT 197.1K
- Earning Date
- OCX 11-12-2024
- DRCT 11-12-2024
- Dividend Yield
- OCX N/A
- DRCT N/A
- EPS Growth
- OCX N/A
- DRCT N/A
- EPS
- OCX N/A
- DRCT N/A
- Revenue
- OCX $709,000.00
- DRCT $94,216,000.00
- Revenue This Year
- OCX N/A
- DRCT $17.00
- Revenue Next Year
- OCX $106.34
- DRCT N/A
- P/E Ratio
- OCX N/A
- DRCT N/A
- Revenue Growth
- OCX N/A
- DRCT N/A
- 52 Week Low
- OCX $1.98
- DRCT $0.58
- 52 Week High
- OCX $3.82
- DRCT $35.88
- Technical
- Relative Strength Index (RSI)
- OCX 29.70
- DRCT 26.06
- Support Level
- OCX $2.33
- DRCT $0.61
- Resistance Level
- OCX $2.48
- DRCT $1.04
- Average True Range (ATR)
- OCX 0.16
- DRCT 0.14
- MACD
- OCX -0.01
- DRCT 0.01
- Stochastic Oscillator
- OCX 39.29
- DRCT 5.73
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.